Glioma of Brain Clinical Trial
Official title:
A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96
This trial is to further study the safety and effectiveness of autologous gp96 treatment of glioblastoma on the basis of preliminary work.
RATIONALE: heat shock protein gp96-peptide complex made from a person's tumor cells may help
the body build an effective immune response to kill tumor cells.
Overall Goals:
- to evaluate the safety and induction of anti-tumor immunity by administration of an
immunogenic human tumor cell vaccine, and assess immune response in relation to clinical
outcome.
Primary Aim:
- to further evaluate effectiveness of autologous gp96 treatment of glioblastoma on the basis
of preliminary work.
Secondary Aims:
to study the immune response to vaccination, to monitor clinical responses , to further the
safety of vaccine.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT03796507 -
Early Temozolomide in Patients With High-Grade Gliomas in Rehabilitation
|
Early Phase 1 | |
| Withdrawn |
NCT04406610 -
CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03665545 -
Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03189420 -
Glioma Microenvironment an Exploratory Study
|
||
| Completed |
NCT03194906 -
Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT03739372 -
Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma
|
N/A | |
| Completed |
NCT03779230 -
Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03728673 -
A Study Utilizing Escitalopram in Glioma Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03496181 -
Evaluation of Functional Magnetic Resonance Imaging (fMRI) in Patients Who Speak Two Languages Fluently
|
||
| Recruiting |
NCT03180697 -
The Efficacy of APT Magnetic Resonance Imaging in Predicting the Efficacy of Bevacizumab in Recurrent Malignant Gliomas
|
N/A | |
| Recruiting |
NCT03949192 -
Efficacy of Kangliuwan for Recurrent Grade IV Glioma
|
||
| Terminated |
NCT03927274 -
Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma
|
Early Phase 1 | |
| Recruiting |
NCT03213002 -
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03763396 -
Azoles Targeting Recurrent High Grade Gliomas
|
Early Phase 1 | |
| Terminated |
NCT03698201 -
Blood Biomarker Signature in Glioma
|
||
| Terminated |
NCT03436433 -
Seizure Prophylaxis in Patients With Glioma or Brain Metastasis
|
Phase 2 | |
| Recruiting |
NCT03750890 -
Visual Study of Molecular Genotype in Glioma Evolution
|
||
| Enrolling by invitation |
NCT03102112 -
Noninvasively Predicting Gene Status of Glioma
|
N/A | |
| Recruiting |
NCT03935685 -
Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ
|
Phase 2 | |
| Completed |
NCT03834740 -
A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection
|
Early Phase 1 |